AveXis to Advance Gene Therapy Program Initiated by the Rett …PR Web (press release)The Rett Syndrome Research Trust (RSRT) is excited to announce that AveXis, Inc., has committed to advance a gene therapy candidate for Rett Syndrome into …and… Continue reading
|
Synovial stem cells respond to a YAP
Nature.com Growth/differentiation factor 5 (GDF5)-lineage mesenchymal stem cells (MSCs) residing in the synovium of adult mice respond to cartilage injury and aid repair via the actions of transcriptional co-activator YAP1, according to new research. “Our … |
|
Synovial stem cells respond to a YAP
Nature.com Growth/differentiation factor 5 (GDF5)-lineage mesenchymal stem cells (MSCs) residing in the synovium of adult mice respond to cartilage injury and aid repair via the actions of transcriptional co-activator YAP1, according to new research. “Our … |
BRINK |
Synthetic Biology: Next Wave of Disruption for Industrialization of Biology
BRINK Synthetic biology—a relatively new field that aims to make biology easier to engineer—is quietly disrupting traditional manufacturing methods, leading to the industrialization of biology and a global market estimated to be worth $11.4 billion by 2021 … |
Columbus Business First |
Nationwide Children’s spins out fourth gene therapy company – this one is staying in Central Ohio
Columbus Business First Nationwide Children’s Hospital has spun out its fourth gene therapy startup to result from decades of research and millions in investment in manufacturing equipment and commercialization personnel. |
WIRED |
Crispr May Cure All Genetic Disease—One Day
WIRED Jennifer Doudna was sitting in her UC Berkeley office when she got the first call from a reporter asking what she thought about scientists using Crispr to modify embryos. At the time, the embryos in question were monkeys. It was late 2014, and Doudna … |
The Scientist |
Was a Drop in CRISPR Firms’ Stock Warranted?
The Scientist ISTOCK, VCHALLast week, a study made headlines worldwide with its claim that the CRISPR-Cas9 genome-editing technique is more error prone than expected. In response, some investors chose to sell their shares in CRISPR-based biotech firms and stock … Someday, MaybeGenomeWeb |